ライフサイエンスコーパス: norepinephrine

1 neurotransmitters (dopamine, serotonin, and norepinephrine).

2 ance the synaptic levels of serotonin and/or norepinephrine.

3 er for serotonin than it is for dopamine and norepinephrine.

4 uestion of a possible noncanonical action by norepinephrine.

5 tial changes in regulation of brain state by norepinephrine.

6 efore and after inducing cardiac stress with norepinephrine.

7 smitters, including L-DOPA, epinephrine, and norepinephrine.

8 n; midodrine; octreotide; noradrenaline; and norepinephrine.

9 ylguanidine (MIBG), a guanethidine analog of norepinephrine.

10 eceptor activation by the endogenous agonist norepinephrine.

11 al to 2 mmol/L, randomized to vasopressin or norepinephrine.

12 ments of related neuromodulators dopamine or norepinephrine.

13 in preparing noradrenaline analogs, such as norepinephrine, (11)C-metahydroxyephedrine, and (123)I-m

14 Norepinephrine (77.6%) was the most frequently used init

15 Norepinephrine, a neuromodulator that activates beta-adr

16 increases sympathetic innervation and local norepinephrine accumulation.

17 Norepinephrine acted as a potent agonist for all D2-like

18 ongbird brain, we tested the hypothesis that norepinephrine actions depend on local estrogen synthesi

19 accessible biological parameter regulated by norepinephrine activation of alpha1ARs on peripheral art

20 Norepinephrine also decreased mRNA expression of osterix

21 Norepinephrine also dose dependently stimulated isoketal

22 mice, and responses to serotonin, but not to norepinephrine, also differed between genotypes.

23 ) excitation and global gain modulation (via norepinephrine) amplifies selectivity in information pro

24 (defect of the positron emission tomography norepinephrine analog (11)C-hydroxyephedrine), lack of a

25 017) uncover how octopamine, an invertebrate norepinephrine analog, modulates the neural pathways tha

26 similarity and the ability to interact with norepinephrine and a number of compounds that bind with

27 The ascending fibers releasing norepinephrine and acetylcholine are highly active durin

28 the different physiological features of the norepinephrine and acetylcholine systems in the light of

29 scription of the immunomodulatory effects of norepinephrine and alternative vasopressors.

30 When challenged with norepinephrine and caffeine to simulate a catecholaminer

31 on, the activities of the central glutamate, norepinephrine and central cytokine systems are signific

32 ute SCI in mice induced suppression of serum norepinephrine and concomitant increase in cortisol, des

33 knowledge, significant interactions between norepinephrine and D2R or D3R receptors have not been de

34 Norepinephrine and dopamine are among the most widely di

35 Our results identify norepinephrine and dopamine as important factors shaping

36 ophysiological effects of the catecholamines norepinephrine and dopamine on stimulus-evoked cortical

37 dence suggests that neuromodulators, such as norepinephrine and dopamine, increase neural gain in tar

38 ped by the catecholaminergic neuromodulators norepinephrine and dopamine.

39 neuronal plasticity and increased levels of norepinephrine and dopamine.

40 n = 101), vasopressin and placebo (n = 104), norepinephrine and hydrocortisone (n = 101), or norepine

41 such dopamine precursors and metabolites as norepinephrine and l-DOPA.

42 e > 2 mmol/L) differ from vasopressin versus norepinephrine and mortality in Vasopressin and Septic S

43 epinephrine and hydrocortisone (n = 101), or norepinephrine and placebo (n = 103).

44 d by mechanisms that include increased fetal norepinephrine and reduced IGF-1 and insulin.

45 tudies on the immunomodulatory properties of norepinephrine and viable alternatives are highly warran

46 Both norepinephrine and withdrawal symptoms could be elicited

47 (1D), high-dose insulin therapy (1D-2D), and norepinephrine and/or epinephrine (1D).

48 enty-three percent were septic, 47% required norepinephrine, and 53% were mechanically ventilated.

49 target monoamine transporters for dopamine, norepinephrine, and serotonin (DAT, NET, and SERT, respe

50 s study, we examined the effect of dopamine, norepinephrine, and serotonin on lOFC neuronal excitabil

51 eart rate dissipated after administration of norepinephrine, and there were no differences in heart r

52 hormonal systems activated in heart failure (norepinephrine, angiotensin II, aldosterone, and neprily

53 ctate measurement during first hospital day, norepinephrine as first vasopressor, and avoidance of st

54 ot support the use of vasopressin to replace norepinephrine as initial treatment in this situation, t

55 uartile 1, 2.8; 95% CI, 2.1-3.7) and receive norepinephrine as initial vasopressor (adjusted odds rat

56 d with septic shock who received dopamine or norepinephrine as initial vasopressor during the first 2

57 Clinical guidelines recommend norepinephrine as initial vasopressor of choice for sept

58 68.3% had lactate measured and 64% received norepinephrine as initial vasopressor.

59 This study reveals epinephrine and norepinephrine as novel regulators of cellular iron home

60 he arguments on the physiological effects of norepinephrine at the cortical level are inconsistent wi

61 l window of opportunity for locus coeruleus/ norepinephrine-based therapeutics exists.

62 n fact, previous studies have suggested that norepinephrine can functionally interact with D4R.

63 validity and generalizability beyond classic norepinephrine circuits because it simplifies extremely

64 t hypothesis was that the vasopressin versus norepinephrine comparison and 28-day mortality of patien

65 compared dopamine transients in the NAc with norepinephrine concentration changes in the vBNST, and c

66 Sustained elevation of norepinephrine concentrations in the blood has been corr

67 ften interpreted in terms of the activity of norepinephrine-containing neurons in the brainstem nucle

68 induced lipolysis accompanied by a decreased norepinephrine content in white adipose tissue (WAT).

69 Norepinephrine contents in the subjects' serum and condy

70 The norepinephrine contents, distribution of sympathetic ner

71 neurotransmitters such as acetylcholine and norepinephrine contributed to neuronal control of target

72 ults in dopamine, serotonin, epinephrine and norepinephrine deficiencies.

73 eta-adrenergic stress induced with 10 microm norepinephrine demonstrated increased susceptibility to

74 Norepinephrine depresses aggrecans expression but stimul

75 , the early use of vasopressin compared with norepinephrine did not improve the number of kidney fail

76 ne group (25.4% for vasopressin vs 35.3% for norepinephrine; difference, -9.9% [95% CI, -19.3% to -0.

77 However, for both dopamine and norepinephrine, differences depended on the Galphai/o pr

78 omodulators, corticotropin-releasing factor, norepinephrine, dopamine, and serotonin to affect the ci

79 k twice, with and without methylphenidate, a norepinephrine-dopamine reuptake inhibitor.

80 oronary percutaneous intervention (PCI), and norepinephrine dose, the mean +/- SD post-arrival increm

81 Norepinephrine dose-response curves showed no HTN-relate

82 light the potential of adrenergic stress and norepinephrine-driven beta-AR signaling to regulate the

83 of epinephrine and a 44% increase in plasma norepinephrine during hypoglycemia compared with placebo

84 fects of different stressors on behavior and norepinephrine dynamics in the BNST of rat strains known

85 in a predictive coding approach, the arousal/norepinephrine effects described by the GANE (glutamate

86 a pattern classifier analysis indicated that norepinephrine enhanced the ability of single neurons to

87 sed by Mather et al. attempts to explain how norepinephrine enhances processing in highly activated b

88 ncomitant vasopressor requirements, based on norepinephrine equivalents excluding vasopressin, were s

89 without a significant effect on 24-h urinary norepinephrine excretion rate.

90 To restore the energy balance, epinephrine/norepinephrine-exposed cells may face higher iron demand

91 The potency of norepinephrine for adrenergic alpha2A receptor was only

92 ls (5.3 +/- 0.1 mmol/L), plasma epinephrine, norepinephrine, glucagon, cortisol, and growth hormone r

93 significant blunting of plasma epinephrine, norepinephrine, glucagon, cortisol, and growth hormone r

94 ed in significant reductions of epinephrine, norepinephrine, glucagon, growth hormone, cortisol, endo

95 f memory by this circuit is modulated by the norepinephrine-glutamate loop described by Mather et al.

96 therapy in the vasopressin group than in the norepinephrine group (25.4% for vasopressin vs 35.3% for

97 group and 93 of 157 patients (59.2%) in the norepinephrine group (difference, -2.3% [95% CI, -13.0%

98 sin group and 13 days (IQR, 1 to -25) in the norepinephrine group (difference, -4 days [95% CI, -11 t

99 in group vs 17 of 204 patients (8.3%) in the norepinephrine group (difference, 2.5% [95% CI, -3.3% to

100 We compared vasopressin-to-norepinephrine group 28- and 90-day mortality in Vasopre

101 ic enhancement, dopamine (bromocriptine) and norepinephrine (guanfacine) manipulations did not improv

102 is circumstantial, as immunologic effects of norepinephrine have not been investigated properly in ex

103 Vasopressin lowered mortality versus norepinephrine if lactate was less than or equal to 2 mm

104 e cells, we still know very little about how norepinephrine impacts signaling pathways in dendritic c

105 s, whereas exposure to sympathetic nerves or norepinephrine imposes arterial fate.

106 So far, no direct role of epinephrine/norepinephrine in cellular iron homeostasis has been rep

107 ) mediates reuptake of synaptically released norepinephrine in central and peripheral noradrenergic n

108 028) lower mortality with vasopressin versus norepinephrine in lactate less than or equal to 2 mmol/L

109 ned vocalizations, and the potential role of norepinephrine in modulating the neuronal computations f

110 images, suggesting a more pervasive role of norepinephrine in perceptual encoding.

111 nged with physiologically relevant levels of norepinephrine in the presence of iron-bound transferrin

112 ite 5-hydroxyindoleacetic acid (5-HIAA), and norepinephrine in the raphe nuclei.

113 ed a careful comparison between dopamine and norepinephrine in their possible activation of all D2-li

114 (LC) (the neuromodulatory nucleus releasing norepinephrine) in urethane-anesthetized rats.

115 We demonstrate the role of epinephrine/norepinephrine-induced generation of reactive oxygen spe

116 uncoupling protein 1 expression and maximal norepinephrine-induced heat production were gradually in

117 Aneurysms and rupture did not occur with norepinephrine-induced hypertension.

118 KCNK3 antagonizes norepinephrine-induced membrane depolarization by promot

119 There is no evidence that norepinephrine induces local "hotspots": Norepinephrine

120 Of note, norepinephrine infusion did not increase DOR or Tp-e.

121 ving protocol-guided parenteral fluids and a norepinephrine infusion to maintain mean arterial pressu

122 guided sedation, ventilation, IV fluids, and norepinephrine infusion.

123 d bilateral stellate ganglia stimulation and norepinephrine infusion.

124 eep fetuses following a 7-day noradrenaline (norepinephrine) infusion.

125 Concealed vasopressin (0.03 U/min.) or norepinephrine infusions.

126 d in liver and muscle tissues of epinephrine/norepinephrine-injected mice.

127 The common overlap of norepinephrine innervation and D2-like receptor expressi

128 he curves for insulin and insulin secretion, norepinephrine, insulin sensitivity, acute insulin respo

129 effects) model proposes that local glutamate-norepinephrine interactions enable "winner-take-more" ef

130 Here, we infused norepinephrine into the zebra finch auditory cortex and

131 Norepinephrine is currently recommended as the first-lin

132 Although norepinephrine is important for cortical plasticity, it

133 findings in rodents and humans indicate that norepinephrine is ineffective in modulating mnemonic pro

134 er subcutaneous injection with vehicle, 1 mg norepinephrine/kg, or 5 mg AITC/kg.

135 stress response, as are the locus coeruleus norepinephrine (LC-NE) and dorsal raphe serotonin (DR 5-

136 Because the locus coeruleus-norepinephrine (LC-NE) system is a major stress-response

137 stress are regulated by the locus coeruleus-norepinephrine (LC-NE) system.

138 locus coeruleus noradrenaline (also known as norepinephrine) (LC-NE) neurons receive input from and s

139 ted subchondral bone loss and decreased bone norepinephrine level in all experimental subgroups when

140 ral bone loss and increased subchondral bone norepinephrine level were observed in the CIS and UAC gr

141 re severe subchondral bone loss, higher bone norepinephrine level, and decreased chondrocyte density

142 Increases in norepinephrine level, sympathetic nerve fiber distributi

143 lication to the renal arteries reduced renal norepinephrine levels and blunted angiotensin II-induced

144 ts displayed progressive loss of hippocampal norepinephrine levels and locus coeruleus fibres in the

145 In all 14 patients with CIPA, plasma norepinephrine levels were very low or undetectable and

146 onomic failure phenotype had very low plasma norepinephrine levels, slow resting heart rate, no REM s

147 nce in concomitance with higher dopamine and norepinephrine levels.

148 staining and resulted in lower transcardiac norepinephrine levels.

149 hat norepinephrine induces local "hotspots": Norepinephrine mainly decreases evoked responses; facili

150 sing immunoparalysis is underway, the use of norepinephrine may aggravate the development, extent, an

151 levate dopamine in addition to serotonin and norepinephrine, may demonstrate greater efficacy, with t

152 complex and heterogeneous actions including norepinephrine mechanisms related to higher cognitive ci

153 Furthermore, disruption of norepinephrine-mediated signaling is strongly associated

154 n humans, with a focus on heart rate, plasma norepinephrine, microneurographic recording of sympathet

155 eus innervation and deficits locus coeruleus/norepinephrine modulated behaviours, does not exist, ham

156 We here show that the neuromodulator norepinephrine modulates olfactory bulb spontaneous acti

157 (versus WT mice at baseline and all doses of norepinephrine), myocardial blood flow was lower in Kv1.

158 35 patients (mechanical ventilation n = 78; norepinephrine n = 13).

159 calf for graded infusions of noradrenaline (norepinephrine) (NA; 10(-12) to 10(-2) m).

160 gic receptor stimulation with noradrenaline (norepinephrine; NA, 50 mul, 250 muM) was applied to elic

161 Here we investigated whether norepinephrine (NE) administration into the basolateral

162 control of the heart is a classic example of norepinephrine (NE) and acetylcholine (ACh) triggering o

163 f neuromodulation by acetylcholine (ACh) and norepinephrine (NE) and afferent synaptic excitation.

164 s catecholamine transmission via blockade of norepinephrine (NE) and dopamine (DA) reuptake transport

165 Diffuse neuromodulatory systems such as norepinephrine (NE) control brain-wide states such as ar

166 Both epinephrine (EPI) and norepinephrine (NE) could directly inhibit breast cancer

167 ught to determine whether the stress hormone norepinephrine (NE) could induce hTERT expression and su

168 Norepinephrine (NE) has been shown to influence sensory,

169 ion factor Nr4a1 regulated the production of norepinephrine (NE) in macrophages and thereby limited e

170 Norepinephrine (NE) is a key catecholamine that stimulat

171 Norepinephrine (NE) is produced primarily by neurons in

172 ith degeneration of the locus coeruleus (LC) norepinephrine (NE) neurons.

173 rmacological studies in mammals suggest that norepinephrine (NE) plays an important role in promoting

174 omplete ECS of the alpha1B-adrenoreceptor on norepinephrine (NE) potency, affinity, and efficacy.

175 rength of a representation and interact with norepinephrine (NE) to enhance high priority representat

176 ransmitter levels of serotonin, dopamine and norepinephrine (NE) were dysregulated from Postnatal day

177 cal redox cycling behavior of dopamine (DA), norepinephrine (NE), and their mixture was investigated

178 nd in Skov3-ip1 and HeyA8 cells treated with norepinephrine (NE), and these changes were shown to be

179 Sympathetic neurons normally make norepinephrine (NE), which increases heart rate and the

180 cellular mechanism(s) linking macrophages to norepinephrine (NE)-mediated regulation of thermogenesis

181 m, whose chief effector is the catecholamine norepinephrine (NE).

182 l depolarization, and the other activated by norepinephrine (NE).

183 -D4 receptors occurred in slices depleted of norepinephrine (NE).

184 autoinducer-3 (AI-3), epinephrine (Epi), and norepinephrine (NE).

185 amines serotonin (SERT), dopamine (DAT), and norepinephrine (NET) are targets of multiple psychoactiv

186 studies to date have examined the effects of norepinephrine on the neuronal response to relatively si

187 pamine or the D2 agonist quinpirole, but not norepinephrine or serotonin, was prevented by the GABAA

188 asis has been on radioligands monitoring the norepinephrine pathway.

189 hock who were receiving more than 0.2 mug of norepinephrine per kilogram of body weight per minute or

190 The catecholamine norepinephrine plays a significant role in auditory proc

191 ctopamine (OA, the invertebrate homologue of norepinephrine), plays a major role in controlled sugar

192 hydroxymandelic acid (DHMA), a metabolite of norepinephrine produced by E. coli, is a chemoattractant

193 coeruleus beyond its primary definition as a norepinephrine-producing nucleus.

194 reset hypothesis" supporting the notion that norepinephrine promotes rapid cognitive and behavioral a

195 Mather and colleagues postulate that norepinephrine promotes selective processing of emotiona

196 , P < 0.0001) were positively associated and norepinephrine (r(2) = 0.59, P < 0.0001) was negatively

197 Here we show that epinephrine/norepinephrine regulates iron homeostasis components suc

198 e interdisciplinary model of arousal-induced norepinephrine release and its role in selectively enhan

199 e important role of alpha2AAR in controlling norepinephrine release and response, this novel regulati

200 at high stress levels (represented by higher norepinephrine release by sympathetic nerves) contribute

201 ary sensory input to the brain by modulating norepinephrine release from the locus coeruleus into the

202 timulation of LC-NE fibers in the BLA evokes norepinephrine release in the basolateral amygdala (BLA)

203 t information through local "hotspots" where norepinephrine release interacts with glutamatergic acti

204 eurons, resulting in reduced firing rate and norepinephrine release.

205 Both circulating epinephrine and norepinephrine released from adrenal medullary chromaffi

206 Most of the norepinephrine released in the brain is supplied by a ve

207 from adrenal medullary chromaffin cells and norepinephrine released locally from sympathetic nerve t

208 Primary outcome was the total amount of norepinephrine required to maintain a target mean arteri

209 hours of study drug infusion, the amount of norepinephrine required was no different between the stu

210 model of septic shock did not markedly alter norepinephrine requirement or any other physiological pa

211 itially started on hemodialysis despite high norepinephrine requirements and ultimately transitioned

212 ne transients in the NAc, but did not elicit norepinephrine responses in the vBNST.

213 venlafaxine-extended release (serotonin and norepinephrine reuptake inhibitor [SNRI]) therapy.

214 Extensive global use of the serotonin-norepinephrine reuptake inhibitor Amitriptyline (AMI) fo

215 tions for a selective serotonin or serotonin-norepinephrine reuptake inhibitor between conception and

216 antidepressant, is a selective serotonin and norepinephrine reuptake inhibitor in humans, and this dr

217 ctive serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor prescription before or

218 ctive serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor use and 11 studies rep

219 ctive serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor users, but uncertainty

220 ed with treatment outcomes for the serotonin norepinephrine reuptake inhibitor venlafaxine.

221 erotonin reuptake inhibitor or serotonin and norepinephrine reuptake inhibitor).

222 eceptor agonist, opioid antagonist, dopamine-norepinephrine reuptake inhibitor, and glucagon-like pep

223 scitalopram and sertraline and the serotonin-norepinephrine reuptake inhibitor, venlafaxine-extended

224 rotonin reuptake inhibitors or serotonin and norepinephrine reuptake inhibitors (collectively: SSRIs)

225 Serotonin-norepinephrine reuptake inhibitors (SNRIs) significantly

226 tonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and placebo

227 nin reuptake inhibitors [SSRIs] or serotonin-norepinephrine reuptake inhibitors [SNRIs], tricyclic or

228 Serotonin-norepinephrine reuptake inhibitors also appear to be eff

229 ctive serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors are among the most co

230 ctive serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors in critically ill pat

231 ctive serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors previously or during

232 ctive serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors were continued in ICU

233 use of tricyclic antidepressants, serotonin norepinephrine reuptake inhibitors, and voltage-gated ca

234 e dopamine-dense nucleus accumbens (NAc) and norepinephrine-rich ventral bed nucleus of the stria ter

235 specific aromatase inhibitor, did not block norepinephrine's neuromodulatory effects.

236 sion and electrophysiological properties and norepinephrine secretion.

237 e amine neurotransmitters, such as dopamine, norepinephrine, serotonin, and trace amines, relies in p

238 At the time of enrollment, plasma norepinephrine, serum NT-proBNP, and lymphocyte GRK2 lev

239 It is less clear how norepinephrine shapes the detection of complex syntactic

240 tals that demonstrated at least 1 quarter of norepinephrine shortage in 2011, norepinephrine use amon

241 ion between admission to a hospital during a norepinephrine shortage quarter and in-hospital mortalit

242 Hospital-level norepinephrine shortage was defined as any quarterly (3-

243 c shock in US hospitals affected by the 2011 norepinephrine shortage, the most commonly administered

244 eption, monoamines (dopamine, serotonin, and norepinephrine) signal via metabotropic receptors.

245 ta support reciprocal roles for dopamine and norepinephrine signaling during drug exposure and withdr

246 icted consequences of age-related changes in norepinephrine signaling for cognitive function?

247 c neurons innervating the gut muscularis and norepinephrine signaling to beta2 adrenergic receptors o

248 ve traffic, and measurements of radiolabeled norepinephrine spillover.

249 d to the following groups: control, esmolol, norepinephrine (started at 18 hr after the surgery), and

250 smolol (started at 4 hr after the surgery) + norepinephrine (started at 18 hr after the surgery).

251 pressed higher levels of beta2-AR and RANKL; norepinephrine stimulation further increased their RANKL

252 alloids (balanced electrolyte solution), and norepinephrine support.

253 chnologies highlight how the locus coeruleus-norepinephrine system can now be targeted with increased

254 ery and maintain basal activity of the brain norepinephrine system in the absence of stress are not f

255 ts that sensitization of the locus coeruleus-norepinephrine system may underlie behavioral and autono

256 was associated with activity of the central norepinephrine system, estimated using pupilometry, for

257 dulatory systems, such as the locus ceruleus-norepinephrine system, which send diffuse projections to

258 vity of an 'arousal' network, related to the norepinephrine system.

259 se is activation of the locus coeruleus (LC)-norepinephrine system.

260 sms both within and outside of the serotonin/norepinephrine system.

261 (ACO2) activity are elevated by epinephrine/norepinephrine that are blocked by the antioxidant N-ace

262 c neurotransmitters, such as epinephrine and norepinephrine, that are known to increase virulence in

263 we discuss the potential detrimental role of norepinephrine, the cornerstone treatment for septic sho

264 associated with a 2011 national shortage of norepinephrine, the first-line vasopressor for septic sh

265 Here we report that norepinephrine, through its actions on beta-adrenergic r

266 The release of the neurotransmitter norepinephrine throughout the mammalian brain is importa

267 nsfusion of shed blood, fluid resuscitation, norepinephrine titrated to maintain mean arterial pressu

268 f differences in the ability of dopamine and norepinephrine to activate different human D4R variants.

269 The Intraoperative Norepinephrine to Control Arterial Pressure (INPRESS) st

270 Chondrocytes were stimulated by norepinephrine to investigate signal transduction of adr

271 The brainstem locus coeruleus (LC) supplies norepinephrine to the forebrain and degenerates in Alzhe

272 y an optimal binding frequency (371.1 Hz) of norepinephrine to the immobilized enzyme on a gold disk

273 Imaging was performed under norepinephrine transport inhibition with desipramine pre

274 th retroviral vectors encoding for the human norepinephrine transporter (hNET), human sodium-iodide s

275 The expression of norepinephrine transporter (NET) and vesicular monoamine

276 The norepinephrine transporter (NET) is essential for norepi

277 The norepinephrine transporter (NET) mediates reuptake of sy

278 we demonstrated a role for p38 MAPK-mediated norepinephrine transporter (NET) Thr(30) phosphorylation

279 at DAT (EC50 approximately 35 nM) and at the norepinephrine transporter (NET).

280 e five putatively functional variants of the norepinephrine transporter (SLC6A2, NET) and serotonin t

281 techolamine levels and neural gain using the norepinephrine transporter blocker atomoxetine and demon

282 thalmic solution, a rho-kinase inhibitor and norepinephrine transporter inhibitor, in patients with o

283 selectivity toward DAT versus serotonin and norepinephrine transporters than modafinil.

284 d that is a potent inhibitor of dopamine and norepinephrine transporters that achieves stable plasma

285 transporters (i.e., serotonin, dopamine, and norepinephrine transporters) have been implicated as pla

286 DHD), which blocks dopamine transporters and norepinephrine transporters, ameliorated the behavioral

287 rrent in vitro and animal data indicate that norepinephrine treatment exerts immunosuppressive and ba

288 ceptor activation had higher skeletal muscle norepinephrine turnover, indicating an increased SNS dri

289 a NET inhibitor chase, mimicking physiologic norepinephrine turnover.

290 inephrine transporter (NET) is essential for norepinephrine uptake at the synaptic terminals and adre

291 The 5-HT uptake inhibitor fluoxetine and the norepinephrine uptake inhibitor desipramine failed to re

292 quarter of norepinephrine shortage in 2011, norepinephrine use among cohort patients declined from 7

293 al in 2011 during which the hospital rate of norepinephrine use decreased by more than 20% from basel

294 Healthcare Database with a baseline rate of norepinephrine use of at least 60% for patients with sep

295 owth factor-1 were positively associated and norepinephrine was negatively associated with hindlimb w

296 utput was decreased during withdrawal, while norepinephrine was released in the vBNST during specific

297 ank order of potencies for both dopamine and norepinephrine were D4R > D2SR = D2LR >> D3R.

298 e hormones/neurotransmitters epinephrine and norepinephrine which are found in the nervous system and

299 rine could have a fundamental advantage over norepinephrine with respect to their immunologic propert

300 n; such processes are partially regulated by norepinephrine within subchondral bone.